Immuno-Oncology | Specialty

KEYNOTE-598 Trial Examining Pembrolizumab/Ipilimumab in NSCLC Stopped for Futility

November 10th 2020

The phase 3 KEYNOTE-598 trial evaluating the dual immunotherapy combination comprised of pembrolizumab and ipilimumab as frontline treatment in patients with metastatic non–small cell lung cancer who have a PD-L1 tumor proportion score of 50% or greater and do not harbor any EGFR or ALK aberrations has been discontinued.

TMB Shows Potential as Immunotherapy Biomarker in Lung Cancer, But Challenges Remain

November 7th 2020

Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.

Nivolumab/Ipilimumab Plus Chemo Approved in Europe for Frontline Metastatic NSCLC

November 6th 2020

The European Commission has approved the combination of nivolumab plus ipilimumab with 2 cycles of platinum-based chemotherapy for the up-front treatment of adult patients with metastatic non–small cell lung cancer without a sensitizing EGFR mutation or an ALK translocation.

JTCC and Georgetown’s Alliance in Cancer Research Achieves New Level With Immunotherapy Breakthrough

November 4th 2020

It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient.

Dr. Patel on the Role of Immunotherapy Combinations in Lung Cancer

November 2nd 2020

Sandip P. Patel, MD, discusses the role of immunotherapy combinations in lung cancer.

Dr. Atkins on the Expanding Role of Immunotherapy in Oncology

October 30th 2020

Michael B. Atkins, MD, discusses the expanding role of immunotherapy in oncology.

Borghaei Stresses Importance of Immunotherapy Biomarkers in Frontline Advanced NSCLC Treatment

October 26th 2020

Hossein Borghaei, DO, MS, further discusses the benefit of immunotherapy combinations, the potential of tiragolumab, and the need for better biomarkers to guide treatment in NSCLC.

Immunotherapy Investigations Lay Groundwork for Future Research Across GI Cancer Settings

October 21st 2020

Manish A. Shah, MD, FASCO, discusses key clinical trials that have evaluated the utility of pembrolizumab and nivolumab in the gastric/gastroesophageal junction cancer, and esophageal squamous cell carcinoma paradigms.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

FIP200 Deletion May Enhance Response to Immunotherapy in Breast Cancer

October 19th 2020

FIP200 deletion was found to enhance the efficacy of immune checkpoint inhibition in patients with nonresponsive breast cancer.

Immunotherapy Expert Puts Fresh Focus on AEs

October 15th 2020

In less than 10 years, immune checkpoint inhibitors (ICIs) have dramatically altered the treatment landscape for patients with metastatic melanoma, helping to drive an improvement in 5-year survival rates from historical levels of less than 10% to more than 50% with some regimens.

Dr. Yap on the Rationale for the SEASTAR Trial in Advanced Solid Tumors

October 8th 2020

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.

Subbiah Tempers Concerns Regarding Pembrolizumab Approval in TMB-High Solid Tumors

October 8th 2020

In our exclusive interview, Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in tumor mutational burden–high solid tumors, shares the “transformative importance” of the regulatory decision, and speaks to the controversy surrounding the approval.

Neoadjuvant Nivolumab/Chemo Combo Significantly Improves pCR in Resectable NSCLC

October 7th 2020

The combination of nivolumab plus chemotherapy resulted in a statistically significant improvement in pathologic complete response when used as neoadjuvant treatment in patients with resectable non–small cell lung cancer, meeting the primary end point of the phase 3 CheckMate-816 trial.

Nivolumab/Ipilimumab Elicits Durable Responses in Refractory Advanced RCC

October 6th 2020

Scott Tykodi, MD, PhD, discusses the FRACTION-RCC study and other novel combinations under exploration for heavily pretreated patients with advanced renal cell carcinoma.

2020 ISGIO Seeks to Simplify Complexities in GI Cancer to Improve Care

October 3rd 2020

Tanios S. Bekaii-Saab, MD, FACP, shares key topics covered in the 17th Annual ISGIO meeting and its significance in the ever-evolving GI cancer space.

Dr. Gerber on the Rationale to Combine Immunotherapy With Radiation in Lung Cancer

October 2nd 2020

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.

FDA Approves Nivolumab/Ipilimumab for Frontline Unresectable Malignant Pleural Mesothelioma

October 2nd 2020

The FDA has approved nivolumab (Opdivo) at 360 mg every 3 weeks plus ipilimumab (Yervoy) at 1 mg/kg every 6 weeks for the frontline treatment of adult patients with unresectable malignant pleural mesothelioma.

Vokes Voices How to Use Genomics to Predict Response to Checkpoint Inhibitors in Cancer

September 26th 2020

Natalie I. U. Vokes, MD, discusses the rise of predictive genomic biomarkers in oncology.

Adjuvant Nivolumab Improves DFS in High-Risk Muscle-Invasive Urothelial Carcinoma

September 25th 2020

Adjuvant nivolumab was found to result in a significant improvement in disease-free survival compared with placebo in patients with high-risk muscle-invasive urothelial carcinoma, including those whose tumors expressed PD-L1 of 1% or higher, meeting the primary end points of the phase 3 CheckMate-274 trial.